Core Viewpoint - The company, Jinxin Fertility (01951), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Share Buyback Details - The company plans to repurchase 3.802 million shares at a total cost of HKD 9.2077 million [1] - The buyback price per share is set between HKD 2.4 and HKD 2.5 [1]

1. 12月9日(周二)美股盘前，美股三大股指 期货涨跌互现。截至发稿，道指期货涨0.06%，标普期货涨 0.08%，纳指期货跌0.03%。 2. 截至发稿，欧洲股市主要指数涨跌互现。欧洲斯托克50指数跌0.21%，英 国富时100指数涨0.07%，法国CAC40指数跌0.61%，德国DAX30指数涨0.3%。 3. 截至发稿，WTI原油 涨0.37%，报59.1美元/桶。布伦特原油涨0.35%，报62.71美元/桶。纽交所 黄金涨0.25%，报4228.3美元/ 盎司。 市场消息 1、国际现货黄金筹码形成双峰分布，两峰之间有筹码缺口区域，需留意两处筹码峰值 对价格运动的影响。 2、美联储年度收官会议中，12名票委及19位成员中抵制降息比例接近半数，鲍威 尔或复制2019年降息加设限策略。 3、国际现货黄金重回4200关口，上方空单密集；美日持续反弹，现 价附近多单挂单密集。 4、美国总统特朗普表示可能降低部分商品关税，立即降息是选择美联储新主席 的试金石。 5、巴西研究提高汽车和 钢铁进口关税。 个股消息 1、英伟达向经美国商务部审核批准的商 业客户提供H200芯片。 2、派拉蒙天舞公司宣布季度现金股息为每 ...

证券之星消息，截至2025年12月9日收盘，通策医疗(600763)报收于41.5元，下跌0.57%，换手率 0.67%，成交量2.98万手，成交额1.24亿元。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 该股主要指标及行业内排名如下： 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 通策医疗2025年三季报显示，前三季度公司主营收入22.9亿元，同比上升2.56%；归母净利润5.14亿 元，同比上升3.16%；扣非净利润5.09亿元，同比上升3.09%；其中2025年第三季度，公司单季度主营收 入8.42亿元，同比上升2.34%；单季度归母净利润 ...

Group 1 - International Medical aims to create a dual-driven development model of "comprehensive medical care + specialized departments" and has announced a plan to raise up to 1.008 billion yuan through a targeted stock issuance [1] - The raised funds will primarily be invested in smart health care projects, the second phase of the proton therapy center, and to supplement working capital [1] Group 2 - The aging population in China is increasing, with approximately 220 million people aged 65 and above expected by the end of 2024, representing 15.6% of the total population [2] - China's total healthcare expenditure has grown from 3.54 trillion yuan in 2014 to 9.06 trillion yuan in 2023, with a compound annual growth rate of 11.01% [2] - The demand for healthcare services is expected to rise due to the increasing elderly population and enhanced health awareness among residents [2] Group 3 - The proportion of nursing beds in registered elderly care institutions in China was 65.7% by the end of 2024, indicating significant growth potential in the elderly care industry [3] - Policies have been introduced to promote the integration of medical and elderly care services, aiming to improve the care system for elderly individuals with disabilities or dementia [3] Group 4 - Proton therapy is highlighted as a cutting-edge cancer treatment method with high cure rates and low side effects, addressing the limitations of traditional radiation therapy [4] - There is a significant market demand for proton therapy in China, with only seven operational proton therapy centers as of 2024, despite approximately 4.8247 million new cancer cases reported in 2022 [4] Group 5 - The health policy framework aims to enhance cancer prevention and treatment systems by 2030, with a planned increase in the number of radiation therapy devices [5] - The proton therapy center's second phase project aligns with national industrial policy and aims to enhance the company's high-end diagnostic capabilities [6] Group 6 - The implementation of the fundraising projects will enable the company to extend its business from traditional diagnostics to high-end radiation therapy, creating a synergistic business model of "comprehensive diagnosis + precise radiation therapy" [6] - The projects will leverage existing medical resources to strengthen the company's core competitiveness in cancer treatment [6]

Core Insights - 2025 is a pivotal year for China's pharmaceutical sector, marked by the implementation of policies aimed at enhancing service quality and accessibility, as well as the transition from the "14th Five-Year Plan" to the "15th Five-Year Plan" [1][2] Group 1: Healthcare System Improvements - Over 90% of township health centers and community health service centers have met basic service capability standards, with many reaching recommended standards [1] - The inclusion of the HPV vaccine in the national immunization program enhances public health protection [1][5] - The proportion of diagnoses from grassroots medical institutions has remained above 50% since the "14th Five-Year Plan" began, indicating a significant role in healthcare delivery [4] Group 2: Medical Insurance and Procurement Reforms - The 11th batch of national drug procurement included 55 drugs across various therapeutic areas, with a focus on maintaining clinical stability and quality [6][9] - The national medical insurance bureau is advancing direct settlements with pharmaceutical companies and optimizing procurement measures to ensure quality and supply [7][9] - The introduction of a commercial insurance directory for innovative drugs marks a significant step in expanding healthcare coverage [11][12] Group 3: Support for Pharmaceutical Innovation - The government has introduced measures to support the development of innovative drugs, including financial backing and streamlined approval processes [10][11] - Approximately 80% of innovative drugs are expected to be included in the medical insurance directory within two years of their market launch [11] - The launch of the drug price registration system aims to facilitate a global pricing strategy for pharmaceutical companies, enhancing their market competitiveness [12]

[Table_Title] 策略研究|策略深度报告 关注"十五五"产业布局的重点方向 [Table_ReportType] ——策略深度报告 [Table_ReportDate] 2025 年 12 月 09 日 | | | | 分析师: [Table_Authors] | 宫慧菁 | | --- | --- | | 执业证书编号： | S0270524010001 | | 电话： | 18028875418 | | 邮箱： | gonghj@wlzq.com.cn | [Table_ReportList] 相关研究 A 股市场投资风格出现切换 A 股三季报盈利能力延续修复 基金配置集中度提升 证 券 研 究 报 告 [Table_RightTitle] 策 略 深 度 报 告 策 略 研 究 ⚫ "十五五"规划建议为产业发展指明方向："十五五"时期 是我国基本实现社会主义现代化夯实基础、全面发力的关 键时期。《建议》将"建设现代化产业体系"作为牵引高质量 发展的首要任务。与"十四五"规划相比，《建议》中现代化 产业体系的内涵更为丰富。三大方向为坚持"智能化、绿色 化、融合化"发展。四项重点任务为优化提升传统 ...

智通财经APP讯，固生堂(02273)发布公告，于2025年12月9日该公司斥资959.73万港元回购34.01万股， 回购价格为每股28.02-28.40港元。 ...

Core Viewpoint - The launch of the National Medical Insurance Administration's drug price registration system reflects a strong support for pharmaceutical innovation and aims to enhance the modernization of drug price governance in China [1] Group 1: Drug Price Registration System - The new system operates on the principles of "one location for acceptance, nationwide sharing, and global openness," providing drug price registration and inquiry services for domestic and foreign pharmaceutical companies [1] - This initiative is expected to facilitate the international expansion of Chinese innovative drugs and attract high-quality new drugs from abroad into the Chinese market [1] Group 2: Market Dynamics - The importance of China's large-scale market in the global pharmaceutical landscape is increasing, leading to higher demands for improving the drug price governance system [1] - The pharmaceutical industry is experiencing a structural recovery trend, with both supply and demand sides reaching a turning point [1] Group 3: Investment Opportunities - The Guotai Medical ETF (159377) tracks the innovative pharmaceutical index (399275), which has a daily fluctuation of up to 20% [1] - This index focuses on innovative pharmaceutical sectors, selecting listed companies with high R&D investment and strong innovation capabilities, reflecting the overall performance of leading companies in the pharmaceutical industry with growth and technological attributes [1]

社会保障信息服务中心分管医疗部门网络安全事务的工作人员李成勋（音译）介绍，如果提前备份 了各项数据，医院就可以在遭黑客攻击后尽快恢复系统数据，需要注意的是数据必须备份在外部硬盘 上，且与主系统处于物理隔离状态。然而，在现实操作中，许多医院没有遵循该原则。 12月4日，在韩国首尔，人们在雪中候车。新华社发（朴晋泽摄） 一些小诊所表示，自己完全无力应对这类威胁。一家诊所甚至表示，给计算机设置密码就是"唯一 能用的安全手段"。 《中央日报》说，在韩国，国立大学的附属医院可从教育部获取网络安全支持，但大部分医院需要 自行购买网络安全支持服务。若是购买社会保障信息服务中心的网络安全服务，每年需支付1200万韩元 （约合5.8万元人民币）至1800万韩元（约合8.7万元人民币）。出于成本考虑等诸多因素，许多医院并 未购买这项服务。在接受调查的270家大型综合医院中，只有20家购买了该服务；在接受调查的7万多家 小型诊所中，只有5家购买了该服务。 新华社北京12月9日电 韩国多家医院近来遭到黑客攻击，有些医院计算机系统被植入勒索软件，还 有的被威胁要曝光患者资料等敏感信息。仅有少数几家大医院迅速作出有效应对，大部分医院以及 ...

Group 1 - The medical services sector increased by 0.09% on December 9, with Zhaoyan New Drug leading the gains [1] - The Shanghai Composite Index closed at 3909.52, down 0.37%, while the Shenzhen Component Index closed at 13277.36, down 0.39% [1] - A table detailing the individual stock performance within the medical services sector was provided [1] Group 2 - The net inflow of main funds into the medical services sector was 514 million yuan, while retail funds experienced a net outflow of 384 million yuan [2] - The net outflow of speculative funds was 129 million yuan [2] - A table showing the fund flow for individual stocks in the medical services sector was included [2]